| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Special Article |
Received April 16, 2001; revised June 22, 2001; accepted June 25, 2001. From the Clinical Antipsychotic Trials of Intervention Effectiveness Program of the National Institute of Mental Health at the University of North Carolina at Chapel Hill. Address correspondence to Dr. Schneider, Professor of Psychiatry, Neurology, and Gerontology, University of Southern California, Keck School of Medicine, 1975 Zonal Ave, KAM-400, Los Angeles, CA 90033. e-mail: lschneid{at}usc.edu
The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.
Key Words: Alzheimer Disease • Clinical Trials • Antipsychotics
This article has been cited by other articles:
|
|
 |
|
  R. A. Rosenheck, D. L. Leslie, J. L. Sindelar, E. A. Miller, P. N. Tariot, K. S. Dagerman, S. M. Davis, B. D. Lebowitz, P. Rabins, J. K. Hsiao, et al. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease Arch Gen Psychiatry, November 1, 2007; 64(11): 1259 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Kales, M. Valenstein, H. M. Kim, J. F. McCarthy, D. Ganoczy, F. Cunningham, and F. C. Blow Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications Am J Psychiatry, October 1, 2007; 164(10): 1568 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Lee, J. A. Hanner, J. L. Yokley, B. Appleby, L. Hurowitz, and C. G. Lyketsos Clozapine for Treatment-Resistant Agitation in Dementia J Geriatr Psychiatry Neurol, September 1, 2007; 20(3): 178 - 182. [Abstract] [PDF]
|
|
|
|
 |
|
 M. T. Beier Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly Am. J. Health Syst. Pharm., January 15, 2007; 64(2_Supplement_1): S9 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Livingston, A E Walker, C L E Katona, and C Cooper Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 25 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Schneider, P. N. Tariot, K. S. Dagerman, S. M. Davis, J. K. Hsiao, M. S. Ismail, B. D. Lebowitz, C. G. Lyketsos, J. M. Ryan, T. S. Stroup, et al. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. N. Engl. J. Med., October 12, 2006; 355(15): 1525 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. McHugo, R. E. Drake, M. F. Brunette, H. Xie, S. M. Essock, and A. I. Green Enhancing Validity in Co-occurring Disorders Treatment Research Schizophr Bull, October 1, 2006; 32(4): 655 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Insel Beyond Efficacy: The STAR{star}D Trial Focus, September 1, 2006; 4(4): 562. [Full Text] [PDF]
|
|
|
|
|
|
D. V. Jeste, T. W. Meeks, D. S. Kim, and G. S. Zubenko Research Agenda for DSM-V: Diagnostic Categories and Criteria for Neuropsychiatric Syndromes in Dementia J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 160 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 A. H. Friedlander, D. C. Norman, M. E. Mahler, K. M. Norman, and J. A. Yagiela Alzheimer's disease: Psychopathology, medical management and dental implications. J Am Dent Assoc, September 1, 2006; 137(9): 1240 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Purandare, R. C. O. Voshaar, J. Hardicre, J. Byrne, C. McCollum, and A. Burns Cerebral emboli and depressive symptoms in dementia The British Journal of Psychiatry, September 1, 2006; 189(3): 260 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lavretsky and L. H. Nguyen Innovations: Geriatric Psychiatry: Diagnosis and Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Psychiatr Serv, May 1, 2006; 57(5): 617 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V Jeste Can Medication-Free Research Ever Be Ethical in Older People With Psychotic Disorders? Schizophr Bull, April 1, 2006; 32(2): 303 - 304. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Aupperle Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 101 - 108. [Abstract] [PDF]
|
|
|
|
|
|
T. R. Insel Beyond Efficacy: The STAR*D Trial Am J Psychiatry, January 1, 2006; 163(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Sirey, B. S. Meyers, J. A. Teresi, M. L. Bruce, M. Ramirez, P. J. Raue, D. A. Perlick, and D. Holmes The Cornell Service Index as a Measure of Health Service Use Psychiatr Serv, December 1, 2005; 56(12): 1564 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Ryu, C. Katona, B. Rive, and G. Livingston Persistence of and Changes in Neuropsychiatric Symptoms in Alzheimer Disease Over 6 Months: The LASER-AD Study Am J Geriatr Psychiatry, November 1, 2005; 13(11): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Layton, S. Harris, L. V. Wilton, and S. A. W. Shakir Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia J Psychopharmacol, September 1, 2005; 19(5): 473 - 482. [Abstract] [PDF]
|
|
|
|
 |
|
 E. D. Rankin and R. D. Layne The Use of Olanzapine in the Treatment of Negative Symptoms in Alzheimer's Disease J Neuropsychiatry Clin Neurosci, August 1, 2005; 17(3): 423 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Gill, P. A Rochon, N. Herrmann, P. E Lee, K. Sykora, N. Gunraj, S.-L. T Normand, J. H Gurwitz, C. Marras, W. P Wodchis, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study BMJ, February 26, 2005; 330(7489): 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Sink, K. F. Holden, and K. Yaffe Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence JAMA, February 2, 2005; 293(5): 596 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E Lee, S. S Gill, M. Freedman, S. E Bronskill, M. P Hillmer, and P. A Rochon Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review BMJ, July 10, 2004; 329(7457): 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Bies, M. R. Gastonguay, K. C. Coley, P. D. Kroboth, and B. G. Pollock Evaluating the Consistency of Pharmacotherapy Exposure by Use of State-of-the-Art Techniques Am J Geriatr Psychiatry, December 1, 2002; 10(6): 696 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. DeKosky Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment: Results From the Cardiovascular Health Study JAMA, September 25, 2002; 288(12): 1475 - 1483. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
